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ABSTRACT 
Objective: To determine the use of complementary and alternative medicine 
(CAM) among adult HIV positive patients in an outpatient setting. 
Design: A prospective, observational study performed on patients diagnosed 
with HIV. The study was conducted from July 2005 to November 2005. 
Setting: An Outpatient clinic at the Department of Sexual Health (DOSH), 
Whipps Cross University Hospital, London.  
Subjects: All patients diagnosed with HIV at the DOSH were approached to 
participate in the project. Data on patients not using CAM and incomplete 
questionnaires were not used in the data analysis process. 
Outcomes measures: The outcome measures include the prevalence of CAM 
use, reasons for using CAM therapies and monthly expenditure with CAM 
therapies, sources of information about CAM therapies, disclosure of CAM 
therapy use, knowledge regarding antiretroviral therapy and CAM therapy drug 
interactions. 
Results: Of the original 81 participants, 38 reported not using CAMs and could 
not complete the questionnaire. Thirty four participants completed full 
questionnaires. Seventy nine percent of participants reported that the main 
reasons for CAM therapy use were the general health advantages and putative 
effect on long-term survival. The most commonly used CAM therapy in this 
study were micronutrients (71%). Monthly out-of-pocket expenditure on CAM 
therapies was < £10 for most participants. No other statistically significant 
results were obtained from the questionnaire.  
Conclusion: Results of this study suggest that CAM therapies are used by HIV 
infected patients to complement conventional treatment and not as an 
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alternative. Multivitamins and minerals were the most commonly used CAM 
therapy. 
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ABSTRAK 
Doel: Om die gebruik van aanvullende en alternative terapieë (AAT) onder 
volwasse MIV positiewe pasiënte in „n buite-pasiënte omgewing te bepaal. 
Studie ontwerp: ‘n Prospektiewe, waarnemende studie uitgevoer op pasiënte 
gediagnoseer met MIV. Die studie het plaasgevind gedurende die tydperk Julie 
2005 tot November 2005. 
Plek: „n Buite-pasiënt kliniek by die Departement van Seksuele Gesondheid 
(DOSH), Whipps Cross Universiteite Hospitaal, Londen. 
Pasiënte: Alle pasiënte gediagnoseer met MIV by DOSH is genader om aan 
die projek deel te neem. Data van pasiënte wat nie AAT gebruik  het nie, asook 
onvoltooide vraelyste is nie in die data-analise ingesluit nie. 
Uitkomste: Die uitkomste sluit  die gebruik  van AAT, redes vir die gebruik en 
maandelikse koste van AAT, bronne van inligting rakende AAT en kennis 
aangaande interaksies tussen antiretrovirale terapie en AAT-gebruik in. 
Resultate: Van die oorspronklike 81 deelnemers het 38 aangedui dat hulle 
geen AAT gebruik nie en kon nie die vraelys voltooi nie. Vier en dertig 
deelnemers het voltooide vraelyste ingevul. Nege-en sewentig persent van 
deelnemers het aangedui dat die hoofrede vir AAT gebruik was die algehele 
gesondheids-voordele en potensiele langtermyn oorlewing. Die mees algemene 
gebruikte AAT in hierdie studie was  mikronutriente (71%). Maandelikse 
uitgawes op AAT terapie was ongeveer £10 vir meeste gebruikers. 
Gevolgtrekkings: Resultate van hierdie studie dui aan dat MIV positiewe 
pasiente AAT gebruik om konvensionele behandeling te komplimenteer en nie 
as ‟n alternatiewe behandeling nie.  Multivitamiene en -minerale was die mees 
algemeenste gebruikte AAT. 
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DEDICATION 
 
 
In ensuring that the millions  
of people who are infected and affected 
 by HIV and Aids are not forgotten, 
 we will not only make a difference to their lives, we will 
also make a difference to our lives as well. We owe this at 
least to humanity. 
 
Give one minute of your life to Aids. 
 
-Nelson Mandela speaking at the 15th International AIDS Conference, Bangkok 
15 July 2004 
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CHAPTER 1: INTRODUCTION AND PROBLEM STATEMENT 
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1.1 Interrelations of HIV Disease, Nutritional Status and Prognosis  
In the pre-Antiretroviral (ARV) treatment era, more than 60% of human 
immunodeficiency virus (HIV) infected people presented with protein energy 
malnutrition (PEM) and vitamin and mineral deficit.1,2,3 This caused significant 
wasting/cachexia and increased susceptibility to opportunistic infections (OI) and 
drug toxicity.1,2,3 The HIV wasting syndrome is defined as weight loss (>10% of usual 
body weight) with fever and/or diarrhoea of unknown origin.4  Some wasting may 
even occur in the absence of these symptoms. Rapid wasting is usually a 
manifestation of OIs or malignancy in late Acquired Immunodeficiency Syndrome 
(AIDS) with advanced immunodeficiency. Weight loss of as little as 5%, specified in 
the Centre for Disease Classification Control and Prevention (CDC) definition may 
also have an adverse effect on disease progression.5 
The introduction of ARV treatment in 1996 has decreased the incidence of wasting, 
and is now seen mostly in patients who have never been treated or where treatment 
has failed due to ARV drug resistance or intolerance. Appendix 1 provides an 
overview of ARV drugs currently available in the United Kingdom (UK) and licensed 
by the European Union (EU). 6 
In addition to wasting syndrome, lipodystrophy is also a common complication of 
ARV treatment especially protease inhibitors. Lipodystrophy manifests as fat 
redistribution with loss of subcutaneous fat, increase in intra-abdominal fat, buffalo 
hump or breast hypertrophy. Body weight may increase or decrease depending on 
the relation between subcutaneous lipoatrophy and intra-abdominal lipohypertrophy.5 
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The prognosis of advanced HIV infection is influenced by loss of body weight. 
Decreased nutritional status, characterised by loss of lean and fat mass, in HIV–
infected patients is associated with an increased mortality, independently of 
immunodeficiency and viral load.7  
The use of CAM has increased over the past decade 8, 9 and has been the focus of 
increased interest from patients, clinicians and investigators.10 Approximately one in 
four persons in the United States (US) use CAM therapy 11 and it is estimated that 
80% of the world‟s population use some form of herbal medicine as part of their 
primary health care.12 A survey in 1989 in the UK showed that 74% of the public 
surveyed were in favour of CAM therapies being made widely available on the 
National Health Service (NHS). In any year it is estimated that 11% of the adult 
population in the UK visited a complementary therapist.13 
 Herbal products were among the most popular CAM therapies, with an estimated 
annual market of $5.1 billion.14 A study by Eisenberg et al. (1993) revealed that over 
30% of Americans have sought treatment from alternative health care practitioners 
and made more visits to these practitioners than conventional health care providers. 
High costs and potentially hazardous side effects of pharmaceutical drugs have been 
partly responsible for this trend.15 The use of CAM therapy is also a common 
phenomenon among patients who suffer from chronic diseases that are either 
untreatable, or for which conventional medical therapy is only partially effective16,17,18  
Although CAM therapy use is often to the detriment of conventional medical 
approaches, it is commonly used in conjunction with conventional therapies.8, 9 
One of the major problems with the use of CAM therapies is the lack of adequate 
research on its efficacy and safety. This applies particularly to herb-drug 
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interactions.14 In the US, herbal products are regulated as dietary supplements under 
the 1994 Dietary Supplement Health and Education Act (DSHEA). This includes a 
framework for safety, labelling, third - party literature provided at the point of sale and 
good manufacturing practice (GMP). It is the manufacturer‟s responsibility to ensure 
that its products are safe and properly labelled prior to marketing. Undoubtedly 
herbal products are not subject to the same strict rules and regulations imposed on 
other over-the-counter and prescription medication. In the UK there are two main 
legal categories of therapeutic and nutritional products under which these products 
can be sold/manufactured: 
1. Licensed medicines: some vitamin and mineral preparations are licensed by 
the Medicines and Healthcare products Agency (MHPA). All products are 
assessed for safety, efficacy and quality in accordance with UK and EU 
legislation. If approved, these products are granted Marketing Authorisation, 
which allows companies to make medicinal claims and assigned the 
appropriate licence status. These products are often indicated for the 
treatment of deficiency states (e.g. HIV – related malnutrition) 19 
2. Unlicensed preparations: Most vitamins, mineral and other supplements are 
treated like food products. They are therefore, controlled under food legislation 
by the Food Standards Agency (FSA) and policed by the local trading 
standards authorities. These companies are not permitted to make any 
medicinal claims related to their products, alleging therapeutic benefit for any 
disease .19 
Therapeutic and nutritional supplements fall within this category of unlicensed 
preparations with a confusing overlap in ingredients, evidence base and routes of 
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supply. The public may use unlicensed products for therapeutic purposes, although 
companies are not required to demonstrate their efficacy before marketing, nor are 
these products subject to prior approval. The main requirements for food related 
products are safety and labelling according to EU guidelines. In addition, companies 
are not allowed to make medicinal claims, however health claims and functional 
claims are allowed.  
As a result there is a lack of evidence based research regarding CAM‟s 
pharmacology, pharmacokinetics, drug interactions, efficacy and safety.20 
1.2 Exploring CAM Therapies  
Several factors influence the choice of CAM therapies. Patients who seek CAM 
therapy may be dissatisfied with conventional medical therapy, desire more control or 
autonomy over decisions involving their health, or see CAM as more compatible with 
their world‟s view and belief system.21 Links with cultural beliefs were specifically 
found to impact on CAM choice, especially in people with a commitment to 
environmentalism, feminism, an interest in spirituality and personal growth 
psychology.21, 22 Individual cultural background and ethnicity also influence CAM 
therapy use.1 
Patients have been shown to engage in self-care practices using CAM therapies as 
true alternatives, thereby placing themselves at risk of delayed diagnosis with 
possible serious consequences.23 There is a general misconception among the 
public that because a product is „natural‟ it is safe, free from side effects and drug 
interactions.19 Considering the widespread use of herbal remedies for various 
medical conditions, and with certain herbal remedies shown to be unsafe or 
  
 6 
potentially unsafe, patients are at risk for both drug-related and disease-related 
problems that may be largely preventable.23  
CAM therapies are a broad term, encompassing many unconventional practices 
including relaxation techniques, spiritual healing, massage, herbal therapy and 
dietary supplementation.  The National Centre for Complementary and Alternative 
Medicine (NCCAM), in the US, defines CAM therapies as a group of diverse medical 
and healthcare systems, practices, and products that are not at present considered 
part of conventional medicine. Conventional medical therapies are defined as 
treatments that are widely taught in medical schools or generally available in 
hospitals.20 
CAM therapies comprise two components namely: 
 Complementary medicine, which is used in addition to conventional     
medicine 
      Alternative medicine, which is used in place of conventional medical therapy 
NCCAM classifies CAM therapies into: alternative medical systems, mind-body 
interventions, biologically based therapies, manipulative and body based methods 
and energy therapies (Figure 1.1).24   
The Cochrane Collaboration (UK) defines CAM as “a broad domain of healing 
resources that encompasses all health systems, modalities, and practices and their 
accompanying theories and beliefs, other than those intrinsic to the politically 
dominant health systems of a particular society or culture in a given historical 
period”.25                                                                                                                                                                                                                                        
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Figure 1.1: Classification of CAM therapies 
1.3 CAM Therapies in HIV   
At the beginning of the HIV epidemic little or no treatment was available for people 
infected with the disease.  HIV-infected people primarily used CAM therapies that 
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allegedly had antiviral or immunostimulatory properties.26 Over the past few years, 
investigators have identified a number of drugs that can slow down the progression 
of the disease as well as therapies to treat the OI.35 ARV therapy and prophylactic 
medications for OI infections have increased the life expectancy for people living with 
HIV/AIDS.35 However, due to their longevity, patients with HIV/AIDS, have more time 
to experience the side effects associated with ARV therapy as well as the disease 
itself.27 The key to effective treatment of HIV infection remains early detection and 
intervention. Early treatment can strengthen the immune system, reduce stress, 
maintain good nutritional status and appropriate exercise regimes. Many of the CAM 
therapies place significant emphasis on these lifestyle issues.37 CAM therapies in HIV 
management may take the form of meditation, massage, acupuncture, spiritual 
healing and other non-pharmacologic therapies, but it is usually associated with 
dietary supplements, vitamins and herbs.20 
During the past few years the public‟s interest in alternative therapies has grown. It 
has been estimated that one in three Americans are currently using some form of 
alternative therapy and among people infected with HIV the proportion is even 
higher.28 De Visser and colleagues 29 found that 56% of their sample (924 
respondents) living with HIV/AIDS in Australia uses CAM therapies.  A number of 
studies have suggested that over half of all HIV-positive men in the US who have sex 
with men (MSM)/bisexual men are using CAM therapies.30 
1.4 Knowledge Regarding Antiretroviral and CAM Therapy Drug Interactions  
Herbal products are commonly used for various purposes and can interact with the 
prescribed ARV drugs in the body (Table 1.1).  These ARV drug - herb interactions 
can result in ARV drug resistance, drug toxicity, treatment failure and ARV treatment 
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side effects.31 Many ARV medications, such as Protease Inhibitors (PIs) and Non–
Nucleoside Reverse Transcript Inhibitors (NNRTIs), are predominantly metabolized 
through the Cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) 
oxidative metabolic pathway and in the case of HIV PIs, are also substrates for drug 
transporters such as P-glycoprotein. Herbal therapies have been shown to affect the 
serum levels of ARV medication through their effects on CYP3A4 metabolism and P-
glycoprotein.32  
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Table 1.1: Commonly used herbal products, purpose for use and known interactions.33 
Herbal 
products 
Purpose for use Known interactions with ARV treatment Outcome Reference 
St. John‟s 
Wort 
(hypericum) 
Depression, anxiety and/or 
sleep disorders 
Induces certain Cytochrome P450 drug-metabolizing 
enzymes in the liver (especially CYP1A2, CYP2C9 
and CYP3A4) and P-glycoprotein (a transport 
protein). Indinavir (PI) and Nevirapine (NNRTI) are 
predominantly metabolized through CYP3A4 
pathway. 
Reduces the blood concentrations of 
Indinavir (PI) and Nevirapine 
(NNRTI) with possible loss of HIV 
suppression. 
34, 35, 36 
Echinacea Prevent colds, flu and other 
infections 
Stimulate immune system to 
help fight infections  
Causes inhibition of CYP1A2 and intestinal CYP3A 
activity and induction of hepatic CYP3A activity.  
Could resulting in elevated levels of 
PIs with increased side effects 
36 
Garlic 
(Allium 
sativum) 
Beneficial cardiovascular 
effect. The most common use 
in terms of HIV. 
Antibiotic properties  
Possible induction of gut mucosal CYP450 3A4 by 
garlic; P-glycoprotein effects are also possible. 
 
Decreased Saquinavir levels as most 
PIs are processed by CYP3A4. 
Therefore, higher than expected 
levels of the drug is in the body 
causing side-effects. 
36, 42 
Milk thistle 
(Silybum 
marianum) 
Hepato-protective effects and 
therefore typically used for 
liver diseases such as 
cirrhosis and hepatitis. 
Relatively small concentrations of milk thistle can 
significantly slow down the activity of the liver 
enzyme CYP3A4 by 50% to 100%. 
 
Should not interfere with Indinavir 
therapy in patients infected with HIV. 
However, caution when using with 
other PI‟s and NNRTI‟s 
41, 42, 43 
Sutherlandia 
Frutescens 
Have antioxidant and anti-
inflammatory potentials 
In-vitro inhibition of CYP3A4 and P-glycoprotein 
expression. Further in-vitro studies also 
demonstrated  propensity for activation of PXR, a 
nuclear receptor that controls the activation of both 
CYP3A4 and P-glycoprotein 
Possible induction of decreased drug 
exposure with prolonged therapy 
38 
Afican Potato 
(Hypoxis) 
Immunostimulant In-vitro inhibition of CYP3A4 and P-glycoprotein 
expression. Further in-vitro studies also 
demonstrated  propensity for activation of PXR, a 
nuclear receptor that controls the activation of both 
CYP3A4 and P-glycoprotein 
Possible induction of decreased drug 
exposure with prolonged therapy 
38 
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1.4.1 St. John’s Wort 
The best-known example and most commonly used CAM therapy in HIV/AIDS 
patients in developed countries is St John‟s Wort (Hypericum perforatum), which has 
documented anti-depressant properties.34 St. John‟s Wort is widely used by people 
with mild depression, often in combination with prescribed antidepressants. Two 
separate small studies done on healthy volunteers, have found that St John‟s Wort 
reduces the concentration of Indinavir 34 and Nevirapine 35 in the body.   
Indinavir a PI, one of the most potent drugs available for treating HIV infection, has 
been shown to prolong survival and slow the progression of the disease34. 
Substances in both St. John‟s Wort and Indinavir share the Cytochrome P450 
metabolic pathway, which suggest the probability of a drug interaction. Plasma levels 
of Indinavir have shown to be substantially reduced by the concomitant use of the 
herbal preparation St. John's Wort, to about 20% of those when Indinavir is given 
alone.36 This may result in suboptimal antiretroviral drug concentrations, leading to 
loss of virologic failure and development of resistance or class cross-resistance. 
A study was conducted in 176 HIV infected people who were using Nevirapine as 
part of their ARV treatment regimen. Five of these patients also used St John's Wort 
concurrently for several months. The study results indicated that the clearance of 
Nevirapine was significantly increased by 35%, thus lowering exposure to 
Nevirapine.34 Therefore the use of Nevirapine together with St John‟s Wort 
(Hypericum) or St John‟s Wort containing products is not recommended.  
Patients taking this specific PI and/or NNRTI‟s should avoid using St. John‟s Wort 34 
as it demonstrates that this commonly used herb perceived to be harmless, may 
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have unsuspected adverse effects on a drug essential to the health of a very 
vulnerable population.  As a result it is recommended that patients keep their doctor 
or pharmacist informed about any use of herbal products.35 
1.4.2 Sutherlandia and African potato (Hypoxis)   
Mills et al. (2005) analysed the effect of two herbs in common medical use in Africa, 
Sutherlandia and African Potato (Hypoxis) for their potential interactions with 
common antiretroviral agent metabolizing mechanisms in vitro.  
Sutherlandia frutescens (common names: Insiswa, Unwele, Mukakana, Phetola, 
Lerumo-lamadi, cancer bush, kankerbos, kankerbossie)37 is a member of the 
Fabacea family.  It has been used in humans in the treatment of cancer, tuberculosis, 
diabetes, chronic fatigue syndrome, influenza, rheumatoid arthritis, osteoarthritis, 
clinical depression and HIV infection. It has been reported that African Potato 
(common names: magic muthi, yellow star, star lily, African potato, sterretjie, Afrika-
patat) is currently been used in some primary health care communities as an 
immunostimulant for patients with HIV/AIDS.37 
The findings by Mills et al. (2005) have identified potential clinically significant drug 
interactions for both Sutherlandia and African Potato (Hypoxis) showing in-vitro 
inhibition of CYP3A4 and P-glycoprotein expression. Further in-vitro studies have 
also demonstrated the propensity for activation of Pregnane X Receptor (PXR), a 
nuclear receptor that controls the activation of both CYP3A4 and P-glycoprotein. 
These findings suggest that the co-administration of these herbal medicines with 
antiretroviral agents may result in the early inhibition of drug metabolism and 
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transport followed by the induction of decreased drug exposure with more prolonged 
therapy.38 
1.4.3 Garlic (Allium sativum) 
Hypercholesterolaemia is a common side effect of ARV treatment and garlic 
supplements are often taken to reduce cholesterol. The main active ingredient in 
garlic, which is known as allicin, has anti-parasitic and antibiotic properties 39 when 
used for gut problems.  Severe gastrointestinal side effects have been reported with 
the simultaneous use of Ritonavir and garlic supplements.34 Piscitelli et al. found that 
garlic supplements reduced the concentration of Saquinavir by more than 50%.40 
Saquinavir concentrations did not return to baseline after the 10-day washout period. 
The cause of prolonged depression in serum concentrations is unknown but may be 
related to a metabolite or component with a long half-life and enzyme-inducing 
capabilities.40 It is recommended that patients should use caution when combining 
garlic supplements with Saquinavir when used as a sole PI.40  
1.4.4 Milk-thistle (Silybum marianum) 
Milk-thistle (Silybum marianum) is an herbal remedy commonly taken by HIV –
infected people for the treatment or prevention of liver disease caused by hepatitis 
and the hepatotoxicicity of HIV drugs.41 Milk-thistle is taken by many people co-
infected with hepatitis C or who have HIV-related drug-induced liver problems. In fact 
some research 39 has hinted at its positive effect on liver health.35 A study conducted 
on 10 healthy volunteers in the US concluded that the co-administration of Milk thistle 
and Indinavir had no apparent effect on Indinavir plasma concentration levels.42 
Furthermore, a study conducted by Mills et al. (2005) on 16 healthy volunteers in 
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Canada found that Indinavir levels were not significantly increased in the presence of 
milk thistle.43 Research has shown that milk thistle should not interfere with Indinavir 
therapy in patients infected with HIV.41    
1.4.5 Echinacea 
Two well-designed studies evaluated Echinacea‟s effectiveness in upper respiratory 
tract infections in the general population. In one study, Echinacea reduced the 
duration of colds and the severity of the symptoms and in the other study Echinacea 
reduced the frequency and number of recurrences.31 However, Echinacea may 
interact with drugs that can cause liver damage, thereby increasing the risk of liver 
impairment. Echinacea may also negate the effects of immuno suppressants, which 
are often used to prevent rejection of organ transplants. Echinacea causes inhibition 
of Cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2) and intestinal 
Cytochrome P450, family 3, subfamily A (CYP3A) activity and induction of hepatic 
CYP3A activity.36 In patients on PIs, this may result in an increase drug levels in the 
blood. Clinicians recommend that people with Type 1 Diabetes, autoimmune 
diseases i.e. rheumatoid arthritis and multiple sclerosis, or diseases of the immune 
system (i.e. impaired by HIV/AIDS or Tuberculosis) should consult their doctor before 
taking Echinacea.32 
1.4.6 Micronutrient use in HIV 
The benefits of vitamin and mineral supplementation in HIV infection remain 
controversial. It has been shown that a healthy well-balanced diet is sufficient to meet 
the recommended intake for vitamin and mineral requirements.44 Large doses of 
some vitamins and minerals can cause unpleasant side effects (e.g. vomiting, 
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abdominal cramping, diarrhoea) and can even be toxic (Table 1.2). 33, 36 In patients 
who are not taking ARV‟s there is evidence that supplementation can slow the 
progression of disease, possibly by redressing the alteration of vitamin and mineral 
levels caused by chronic infection. Between April 1995 and August 2003, 1078 HIV 
infected pregnant women in Dar es Salaam, Tanzania were recruited to examine the 
effect of daily supplements of vitamin A (in the form of vitamin A and beta carotene), 
multivitamins (vitamins B, C, E and folic acid), multivitamins plus vitamin A or placebo 
on the progression of HIV disease.2 Women who received multivitamins had 
significantly higher CD4+, CDS+ and CD8+ cell counts and lower viral loads 
compared to the placebo group. In addition to enhancing immunity, multivitamins 
may also reduce viral replication, as indicated by the reduction in viral load. This 
study concluded that multivitamin supplementation delay the progression of HIV 
disease - thus delaying the initiation of ARV treatment in HIV infected women.2 
Whilst the result suggests that nutritional status may affect the course of HIV 
disease, it is not known whether vitamin supplements delay HIV disease progression 
among people with superior nutritional status compared with participants in the 
study.45 
A study conducted in Thailand found that supplementation with a wide spectrum 
micronutrient tablet was associated with a reduced risk of death in people with 
advanced HIV disease. Although supplementation had no significant effect on CD4+ 
cell count, plasma viral load or clinical disease progression,  people with CD4+ 
counts between 101 and 200 cells/mm3 who received the supplement in this placebo-
controlled study were 67% less likely to die during the 48 weeks study. People with 
CD4+ cell counts less than 100 cells/mm3 who received the supplement were 75% 
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less likely to die. No impact was seen, however, at CD4+ counts above 200 
cells/mm3. Supplementation was also not found to affect the risk of hospital 
admissions.46  
Fawzi et al. (2006) also examined the effect of vitamin supplementation on quality of 
life and the risk of elevated depressive symptoms on 1078 HIV-positive women in 
Dar es Salaam, Tanzania.47 They concluded that multivitamin supplementation (B-
complex, C and E) resulted in a reduction in risk of elevated depressive symptoms 
comparable to major depressive disorder and an improvement in quality of life. 
However, Vitamin A did not have the same impact. 
In patients taking ARV treatment, a broad-spectrum micronutrient formula developed 
by a Californian HIV practitioner has been shown to significantly increase CD4 cell 
counts by 25% over 12 weeks when used as an adjunct therapy to ARV treatment. 
The micronutrient was tested in a randomised and placebo-controlled study involving 
40 HIV-infected people with peripheral neuropathy. The specially designed 
micronutrient combined 15 minerals, 15 vitamins and the anti-oxidants alpha lipoic 
acid, N-acetyl cysteine (NAC) and acetyl L-carnitine. Neuropathy scores improved by 
42% in the micronutrient group compared to 33% improvement in the placebo group. 
However, the difference did not reach statistical significance. The conclusion was 
that micronutrient supplementation can significantly contribute to CD4+ cell count 
reconstitution in HIV-infected patients taking ARVs.48 
In spite of this a recent editorial has called for more research into the benefits and 
limitations of micronutrient supplementation, both in patients taking ARV treatment 
and those that do not. There is also uncertainty surrounding the benefits of vitamins 
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and minerals in reducing oxidative stress and bone loss, and their effects in patients 
co-infected with tuberculosis or hepatitis B or C.1 
Table 1.2: Toxicity of some vitamins and minerals commonly used in HIV.33, 36 
Dietary 
supplement 
Toxicity Caution with ARV  
Vitamin A Doses above 9mg for men or 7.5mg for women may be 
harmful. Large amounts can cause liver and bone damage, 
vomiting and headache. Pregnant women should not take 
supplements containing vitamin A before consulting their 
doctors as high intakes may harm the unborn child.  
None known 
Vitamin C Doses above 1000mg per day .May lead to kidney stones  Special care is needed if taking 
Indinavir (Crixivan). 
Vitamin E Doses above 800mg per day Associated with adverse 
effects; special care is needed if patients are taking anti-
coagulants or have haemophilia.  
Agenerase capsules contain 
vitamin E (36 IU/50 mg capsule), 
therefore additional vitamin E 
supplementation is not 
recommended. Formulations of 
Amprenavir (PI) provide high 
daily doses of vitamin E. Adult 
and paediatric patients should 
be advised not to take 
supplemental vitamin E since 
the vitamin E content of 
Amprenavir capsules and oral 
solution exceeds the Reference 
Daily Intake (adults 30 IU, 
paediatrics approximately 10 IU) 
Vitamin B6 More than 2g per day associated with nerve damage, but 
even doses as low as 50mg per day have been associated 
with peripheral sensory neuropathy 
None known 
Zinc More than 75mg per day have been linked with copper 
deficiency, a shortage of neutrophils, and anaemia. 
None known 
Selenium More than 750µg per day are associated with immune 
suppression 
None known 
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1.5 Choosing CAM Therapies 
Many HIV-infected people are exploring CAM therapy as a means to relieve HIV-
related symptoms and, in some cases, to inhibit viral activity.7,49 The more 
symptomatic the patient, due to disease progression or drug side effects, the more 
likely the patient is to supplement with CAM.50 The opportunity to manage certain 
symptoms of the HIV disease may not only improve patient wellbeing but also 
influence immune status and integrity in this population.26 In a clinical trial among 100 
HIV-infected patients in the US, the most commonly reported reasons for CAM 
therapy use was: nausea, insomnia, dermatological problems, weakness and 
depression.51 Moreover, a study performed on 180 HIV-infected patients attending a 
general medical practice, symptoms such as weight loss, nausea, and diarrhoea 
prompted many of the patients to try herbs, vitamins and supplements for symptom 
relief.8 Primary reasons according to Calabrese et al. (1998) for seeking CAM 
therapies such as acupuncture and massage were pain, depression and stress.52 
Current research suggests that HIV-infected patients are turning to CAM therapy in 
the hope of reducing symptoms associated with HIV/AIDS, managing the side effects 
of drug therapy, maximising quality of life, slowing disease progression, as a way to 
better cope with their illness.28,47,53 Most people living with HIV/AIDS (PLWHA) in the 
UK do not choose CAM as an alternative to ARV treatment, but use CAM to 
complement ARV treatment.29 
1.6 Socio-economic and Demographic Influences  
Research suggests that CAM therapy use is more likely among women, MSM 52, 
young and educated PLWHA.8,51 In earlier research Tsao et al. (2005) found that 
patients with high school or less education (relative to a bachelor‟s degree or more) 
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was less likely to use CAM therapies. Moreover, patients with CD4+ counts below 
500 were likely to use fewer CAM therapies than those with CD4+ counts of 500 or 
more.  
More current research56 indicates that sexual orientation and socio-economic class 
also impact on CAM use:  MSM from middle-class backgrounds are more likely to 
have used complementary therapies. Non-Caucasian MSM with HIV/AIDS viewed 
complementary therapies as an aspect of their cultural heritage, whereas intravenous 
drug users situated their use of CAM therapies to health care in relation to issues 
concerning addiction and rehabilitation.56 
1.7 Where do HIV Infected Individuals Gather Information about CAM Therapies 
Sources to gather information on CAM therapies are varied but include CAM 
providers (Alternative health practitioners), physicians, books, resources from AIDS 
Service Organizations, the internet and health food stores.57 According to De Visser 
et al. (2002) PLWHA appear to be more involved in the HIV/AIDS community – they 
are more likely to read HIV/AIDS magazines/newspapers, and spent more free time 
with other PLWHA.29 
1.8 Disclosure of CAM Therapy Use 
Despite the potential risks of CAM therapy, there is evidence that physician – patient 
disclosure and dialogue about CAM therapy use is infrequent.6,31 A study on US adult 
patients found that 72% of patients did not inform their physician about their CAM 
use.7 These patients had symptoms that ranged from diarrhoea, nausea and vomiting 
and hypertension. As a consequence the physician prescribed allopathic treatments 
without knowing the full context of their patients‟ symptoms. Without knowing about a 
  
 20 
patient‟s use of CAM therapies, the allopathic physician has little basis for 
understanding fluctuations in the patient‟s condition.57 
1.9 Purpose of this Study 
Studies have shown that the use of CAM therapies among adult HIV-infected 
patients is on the increase worldwide.6, 7 Healthcare professionals in developing 
countries are more used to patients using CAM therapy, however in the UK, this is 
still relatively new and many health professionals are not familiar with these products. 
Limited evidence is available in the UK regarding the safe and effective use of CAM 
in the treatment of HIV/AIDS and its complications. The main purpose of this study 
was to establish the prevalence of CAM therapy use among adult HIV-infected 
patients attending an outpatient clinic at Whipps Cross University Hospital, London, 
UK.  Additionally this study was also aimed at exploring reasons for CAM therapy 
use, factors that would impact on the decision to consume CAM therapies and the 
fiscal burden of CAM therapies on an individual with HIV.  
The results of the study would be used to educate local healthcare professionals in 
the use of CAM therapy, in the light of the previously mentioned potential drug-herb 
interactions.  
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2.1 Aim 
The aim of this research project was to determine the prevalence of CAM therapy 
use amongst adult HIV infected patients in an outpatient clinic at Whipps Cross 
University Hospital, London, UK. 
 
 2.2 Objectives 
To determine the following specific objectives: 
1. Reasons for using CAM therapies and monthly expenditure with CAM  
           therapies. 
2. Resources for information about CAM therapies. 
3. Disclosure of CAM therapy use to a doctor or other health care 
           professional. 
4. Knowledge regarding interactions between antiretroviral therapy  
 and CAM therapies. 
2.3 Null-Hypothesis 
Complementary and alternative medicine is not used in people living with HIV/AIDS 
in the UK.  
2.4 Study Design 
A prospective, observational study was performed on patients diagnosed with HIV. 
The study was conducted between July 2005 and November 2005 in the Department 
of Sexual Health (DOSH), Whipps Cross University Hospital, London, UK 
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 2.5 Study Population 
The study population attending the DOSH came from the London Borough of 
Waltham Forest in East London, England and forms part of Outer London consortium 
(Appendix 1). Out of the 376 local government districts in England and Wales, 
Waltham Forest has the 11th largest non-white minority ethnic population. The 
largest minority ethnic group are black Afro-Caribbeans/Africans with a population of 
30,300, followed by Pakistanis who number over 17,000. Out of the 376 local 
government districts in England and Wales, it ranks 19th for over-crowded housing 
conditions, 29th for unemployment and 17th for number of single-parent households.  
 
The total numbers of patients with diagnosed HIV infection in DOSH, Whipps Cross 
Hospital (Waltham Forest), in 2004 was 561 and for North East London 4031 (Table 
2.1). More recent data is not available on this area.60 
  
Table 2.1: Diagnosed HIV prevalence by age group in 2004 
 England London 
Waltham 
Forest 
 2004 2004 2004 
Age (years) N N N 
0 - 14 1310 714 27 
15 - 24 1677 754 21 
25 - 39 19778 10294 289 
40 - 54 13425 7654 200 
55+ 2579 1258 24 
All ages 38769 20675 561 
Source: Survey of Prevalent HIV Infections Diagnosed (SOPHID), 2005 
 
The reason for choosing this population and area for the research project was related 
to the investigator being based at this DOSH clinic. 
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2.6 Sampling Method 
The sampling method used was convenience sampling. Patients were approached 
by the investigator at DOSH, between July 2005 and November 2005 and asked to 
participate in this study. All patients attending the outpatient clinic that were already 
diagnosed with HIV regardless of gender and ethnicity, between the ages of 18-60 
were eligible for inclusion in the study. Patients that did not speak English were also 
included, as there was a translation service available to the DOSH. Patients were 
only excluded if they were aged 61 years and older (as there were no HIV positive 
patients older than 60 registered in the clinic) less than 18 years, or inpatients in the 
hospital. Patients that were not willing to participate were not included in the study. 
The use of CAM therapy was established once the patient was enrolled in the study 
and this data was used for further analysis.   
 
The number of patients in this study was dependant on the attendance of patients 
during the period as well as consent obtained from the subjects.  The investigator 
was aiming to recruit 100 patients out of the 561 patients currently diagnosed with 
HIV in this DOSH at Whipps Cross Hospital. 
 
2.7 Questionnaire Development 
The questionnaire (Appendix 4) for self-administration was developed by reviewing 
the last 2 years dietetic records for the most commonly used CAM therapy in the 
area. In addition an extensive literature search was performed; using only reputable 
peer reviewed resources. Although a plethora of information is available in the lay 
press on CAM therapy, these resources were deemed not suitable for this study, due 
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to the lack of evidence base and peer review. The Pubmed database was searched 
for relevant literature. Searches were limited to English language only. 
  
The following terms were used: “HIV/AIDS, CAM therapies”, “herbal remedies, 
African traditional remedies”, “drug interactions, herbal remedies, antiretroviral 
treatment”, “HIV, complementary therapies”, “St. John‟s Wort, antiretroviral 
medication, drug interactions”. Following the literature search the investigator 
reviewed all available studies and excluded those that were not related to the study. 
The content validity of the questionnaire was therefore based on the available 
literature.   
 
After consultation with the Research and Development Team at Whipps Cross 
Hospital regarding questionnaire development, advice was given to keep 
questionnaires as short as possible to increase patient participation. This advice was 
based on previous studies conducted at DOSH. 
 
The questionnaire consisted of 4 sections (Table 2.2). All patients had to complete 
section A (2 questions) and section B (3 questions). The last 2 sections in the 
questionnaire were different: Section C (8 questions) was completed by patients not 
on HIV treatment and Section D (10 questions) was completed by patients on HIV 
treatment.   
 
The 4 sections of the questionnaire were divided into the following: information about 
the respondent‟s socio-demographical status, HIV status, ARV treatment naivety and 
ARV treatment experience. The questionnaire used a tick-box format, which were 
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converted to numeric values for data analyses. The coding system ensured that the 
information could be easily entered into a computer (Table 2.2). 
 
To avoid confusion and ensure correct interpretation of questions, the questions were 
clearly worded in simple language, which could be understood by all respondents. 
Subsequently, face validity was tested in a pilot study questionnaire at Newham 
General Hospital, London on patients with a similar medical history to ensure face 
validity. The pilot study was conducted during May 2005 and 10 patients completed 
the questionnaire. The HIV centre at Newham General Hospital, where the pilot study 
was performed, provided an unbiased, but similar HIV population to the DOSH at 
Whipps Cross Hospital, as that the hospital was also within the East London 
Consortium. Feedback form the pilot study was positive and no changes were 
necessary. However the feedback from the local Research and Development 
Committee indicated that the questionnaire was too long (12 pages). Therefore the 
font size of the questionnaire was reduced from 12 font to 10 font, which reduced the 
number of pages of the questionnaire to 8 pages. The study population at the 
research centre was therefore not consulted to obtain face validity of the 
questionnaire. 
 
In addition to socio-demographic data (age, gender, education level and employment 
status), respondents indicated the time frame since awareness of HIV positive status, 
their self-perceived state of current health and if they currently use ARV medication. 
Those using ARV medication indicated whether they experienced any side-effects 
taking ARV medication, time period since taking ARV treatment. All respondents 
were asked if they currently used CAM therapies and then had to indicate the types 
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of CAM therapies used, their monthly expenditure on CAM, reasons for using CAM 
therapies, sources of information on CAM, at what point CAM was initiated. 
 
In line with the official CAM therapy classification, the questions on CAM therapy use 
were categorised into 3 groups (Figure 1.1): 
 Herbal remedies 
 Nutritional supplements/vitamins and  
 Lifestyle/ homeopathy. 
 
Participants also indicated whether they had consulted a doctor or other health care 
professional before CAM usage and if they were aware of any herb-drug interactions. 
Some participants indicated the use of CAM therapies from multiple categories. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 28 
Table 2.2: Questionnaire description 
Sections Description Content 
A Socio-demographic information Education level 
Employment status 
B HIV status Time frame since awareness of HIV status 
Patients‟ current state of health (self- perceived) 
Use of HIV medication  
C ARV treatment naïve patients Complementary and alternative therapies categorised 
under herbal remedies, nutritional 
supplements/vitamins and lifestyle/homeopathy 
At what point in time CAM was initiated 
Reasons for using complementary and alternative 
therapies (CAM)  
Sources of information on CAM 
D ARV treatment experienced patients Time frame of anti-HIV treatment usage 
Symptoms experienced 
Complementary and alternative therapies categorised 
under herbal remedies, nutritional 
supplements/vitamins and lifestyle/homeopathy 
At what point in time was CAM initiated 
Reasons for CAM usage  
Sources of information on CAM 
Monthly expenses concerning CAM 
Were  health care professionals consulted before 
CAM usage 
Awareness concerning herb-drug interactions 
 
2.8 Data Collection 
An information sheet (Appendix 2) explaining the purpose of the study was issued to 
all potential participants by the investigator when they attended the clinic for their 
viral load and CD4+ count testing (clinic attendance 1) between July 2005 and 
November 2005 (Figure 2.1). Patients had 2 weeks to consider whether or not to 
participate in the research project. As per clinic procedure, patients normally attend 
their consultant appointment after 2 weeks from the date they had their viral load and 
CD4 count testing. Patients then indicated to the investigator that they wanted to 
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participate in the project. The investigator was available four days of the week in the 
DOSH. Figure 2.1 gives and schematic outline of the process of data collection for 
this project. 
 
 
Figure 2.1: Flow chart of data collection 
 
Participants were given a guarantee that all responses in the questionnaire would be 
kept anonymous and confidential (as indicated in the information sheet) and that 
participation in the project would not prolong their waiting time to see the clinic 
consultant. Participants did not have to sign a consent form as this project was 
regarded as an audit, which formed part of the current clinical practices (UK Ethics 
Committee policy). The completion of the questionnaire was accepted as signed 
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consent. In order to ensure confidentiality, each participant received a reference 
number that was used on all documentation. The questionnaire (Appendix 4) was 
then given for self-completion in a private clinic room, whilst attending the clinic. On 
completion, participants placed the questionnaire in the return box for completed 
questionnaires which was located at the clinic‟s receptionist desk. The Investigator 
data Collection form (Appendix 5) was then completed by the investigator for each 
participant in the study with correlated reference numbers. 
 
Subjects were offered the support of a translation service which was available from 
Waltham Forest Interpretation Service from the London Borough of Waltham Forest 
Council. Participants who required translation could do so through the Patient 
Advisory and Liaison Service (PALS). All interpreters were trained to translate 
medical information and the investigator spent time with the interpreter to explain the 
purpose of the study and questionnaire.  
 
2.9 Data Analysis  
A statistician appointed by the Faculty of Health Science, University of Stellenbosch, 
analysed the data.  Statistica 7.1, SAS and SPSS 14 were used for all statistical 
analysis.  
 
Descriptive data of the subjects was presented as mean, median and standard 
deviations (SD) and the frequency and type of CAM therapy was presented in 
percentages. Cross-tabulation was used to determine prevalence and reasons of 
CAM use and expenses. The maximum likelihood chi-square test for nominal data 
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was used to establish whether CAM therapy use was related or due to gender, race, 
and education. 
 
Data checking and screening took place before formal data analysis by the 
investigator. Data was excluded from formal data analysis if the questionnaire was 
incomplete.   
 
2.10 Ethics Approval and other Considerations  
Ethics approval was obtained from the Human Research Committee of Stellenbosch 
University (Ethics Reference Code N05/07/108). The NHS did not require Research 
and Ethics Committee approval as this project was regarded as an audit, which forms 
part of the current clinical practices. Therefore no written consent was required for 
this study. All information that was collected during the course of the study was kept 
confidential. Anonymous data was stored on a personal computer, which was 
password protected. Completed questionnaires were kept in a locked filling cabinet at 
the DOSH.  
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3.1 Sample Description 
There were 561 HIV positive patients registered at the DOSH, Whipps Cross Hospital 
in 2004. All patients that attended the Whipps Cross Hospital HIV Clinic (DOSH) 
during July 2005 and November 2005 (N = 367) were given the opportunity to 
participate. Only 112 patients were prepared to take the time to read through the 
patient information sheet.  From these 112 patients, 81 patients (72% of total) agreed 
to participate and therefore received a questionnaire. The main reasons for not 
participating in the study were issues related to confidentiality and time constraints as 
documented in the medical notes by the clinic consultant. Thirty eight participants 
(47%) of the 81 patients indicated that they had never used CAM therapies and 
therefore did not complete the questionnaire. Thus, a total of 43 (53%) of the 81 
patients had used CAM therapy and completed the questionnaire. However 9 (21%) 
of the 43 questionnaires were incomplete and could not be included in data analysis. 
Missing data included incomplete reference numbers as allocated by the investigator, 
and socio-demographic information. Therefore, only 34 (79% from 43 questionnaires) 
remained eligible for data analysis (Figure 3.1). None of the 34 study participants 
required the translator services. 
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Figure 3.1: Schematic outline of completed questionnaire 
 
The investigator data collection sheet was used to collect the demographic 
information of the study participants i.e. gender, age and ethnic origin. As well as the 
demographic information, the investigator data collection sheet was used to establish 
how many of the study participants was using ARV treatment or not. 
 
The patients included in the study (N= 34) consisted of 10 women (29%) and 24 men 
(71%). The average age was 39.5 (age range 28 to 61 years; Standard Deviation 
(SD) 8.614) (Table 3.1). 
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Demographic analysis indicated that 17 subjects (50%) were Caucasian and 
represented a range of ethnic backgrounds, including British, Irish and French. 
Another 16 subjects described their ethnicity as Black (47%) (African or Caribbean 
descent) and 1 subject describe his ethnic origin as Chinese (Table 3.1). 
 
Educational level included patients with Secondary/High School (N = 5), College (N = 
13), University Degree (N = 10) and Post Graduate Education (N = 6) (Table 3.1). No 
significant difference between patients‟ use of CAM therapies and educational level 
was found (p = 0.17). 
 
From the total sample (N = 34) 15 participants (44%) were unemployed (Table 3.1).  
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Table 3.1.Demographic description of the sample 
  N = 34 % 
Gender Male 
Female 
24 
10 
71 
29 
Ethnic origin Caucasian 
Black African 
Black Caribbean 
Other 
17 
15 
1 
1 
50 
44 
3 
3 
Age Mean age of patients in years  
Standard Deviation 
Age range 
39.5 years 
8.614 
28 – 61 years 
 
Using ARV Yes 
No 
26 
8 
76 
24 
Education Secondary/High School 
College 
University 
Post Grad Education 
5 
13 
10 
6 
15 
38 
29 
18 
Employment Full time paid employment 
Part time employment 
Self employed/freelance 
Unemployed 
Student 
8 
4 
4 
15 
3 
24 
12 
12 
44 
9 
 
Of the 34 questionnaires that remained eligible for data analysis, 26 (76%) 
participants were on ARV treatment. The remaining 8 (24%) were ARV treatment 
naïve. Using the Chi-square test to compare the ARV group (N = 26) and the non – 
ARV group (N = 8), there was a statistical difference between the two groups (p = 
0.002) for ethnicity (p = 0.000) and gender (p = 0.002) (Table 3.2). However, there 
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was no statistical difference between the ARV group and non-ARV group in terms of 
age.  
 
Table 3.2 Test Statistics for age, gender and ethnicity 
 
  
Difference between ARV 
and non-ARV Group Age Gender Ethnicity 
Chi-Square 9.529 5.118 5.765 29.529 
df 1 18 1 4 
Asymp. Sig. .002 .999 .016 .000 
 
Twenty three (67%) of the participants in this study (N = 34) have been living with 
HIV for 5 years or less. The remaining 11 participants (33%) of the sample (N = 34) 
indicated that they have been living with their HIV diagnosis for more than 5 years. 
 
In response to the question regarding current state of health, 18 subjects (53%) of 
the total sample (N = 34) described their health status as good, 18% (N = 6) 
indicated their health status as fair, 34% (N = 5) chosen excellent, 12% (N = 4) as 
poor and the remaining 3% (N = 1) indicated health status as very poor. 
 
3.2 Study Outcomes in terms of Objectives  
3.2.1 Prevalence of CAM therapy use  
From the 81 patients that agreed to take part in study, 34 patients (53%) used CAM, 
and 47% did not used CAM therapy. Fifteen subjects (44%) indicated that they took 
garlic, 27% (N = 9) took Ginseng, 27% (N = 9) took Echinacea (Table 3.3). Other 
herbal remedies consumed included Chinese Medicine (18%, N = 6), St. John‟s Wort 
(18%, N = 6) and Avurvedic medicine (15%; N = 5). Twenty four subjects (71%) 
reported that they took a multivitamin/mineral, 41% (N = 14) took vitamin E, 38% (N = 
13) took selenium, 12% (N = 4) took glutamine and 18% (N = 6) reported „other 
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nutritional supplement/therapies‟ use. Other CAM therapies included Ginko Biloba (N 
= 1), cod liver oil (N = 1), recreational drugs (Cocaine, Crystal Meth) (N = 1), 
physiotherapy (N = 1), Milk Thistle (N = 1), reflexology (N = 2), 
dehydroepiandrosterone (DHEA) hormone (N = 1). CAM therapies used by fewer 
than 10% of participants included Tibetan Medicine, Sutherlandia, African Potato 
(Hypoxis) and chiropractic therapy. 
 
In the Lifestyle/homeopathy section, 50% (N = 17) indicated that they exercised 
regularly, 32% (N = 11) had regular massages, 24% (N = 8) prayed regularly, 24% (N 
= 8) had regular acupuncture. Meditation/visualization and Reiki was practised by 
15% (N = 5) respectively. Yoga was practised by 12% (N = 4).  
 
All of the participants indicated the use of CAM therapies from multiple categories. 
Statistical analyses using the maximum likelihood chi-square test compared CAM 
use of the ARV treatment group (N = 26) to the non – ARV treatment group (N = 8). 
No statistically significant difference (p = 0.57) between the two groups was found. 
Nineteen (73%;N = 19) participants who were taking ARV treatment started CAM 
therapy after diagnosis and the remainder commenced CAM prior to diagnosis. Five 
(63%) participants from the non-ARV group started CAM prior to diagnosis and the 
remainder commenced CAM after HIV positive diagnosis.  
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Table 3.3: Most commonly used CAM therapies 
CAM N (%) 
Herbal remedies 
Garlic 
Ginseng 
Echinacea 
Chinese medicine 
St. John’s Wort 
Ayurvedic medicine 
Other 
Sutherlandia 
African Potato (Hypoxis) 
Tibetan medicine 
 
15 (44) 
9 (27) 
9 (27) 
6 (18) 
6 (18) 
5 (15) 
4 (12) 
2 (6) 
2 (6) 
0 (0) 
Nutritional Supplements/Vitamins 
Multivitamin/mineral supplements 
Vitamin E 
Selenium 
Other 
Glutamin 
 
24 (71) 
14 (41) 
13 (38) 
6 (18) 
4 (12) 
Lifestyle/Homeopathy 
Exercise 
Massage 
Prayer/Faith healing 
Acupuncture 
Meditation/visualization 
Reiki 
Yoga 
Other 
Chiropractic therapies 
 
17 (50) 
11 (32) 
8 (24) 
8 (24) 
5 (15) 
5 (15) 
4 (12) 
4 (12) 
1 (3) 
*Combinations of CAM therapies excluded; all patients used multiple CAM therapies 
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Twenty nine participants (85%) did not believe that CAM therapies cured HIV/AIDS. 
Only 5 participants (15%) indicated that they believed that CAM therapies did indeed 
cure HIV/AIDS. 
 
3.2.2 Reasons for using CAM therapies and monthly expenditure with CAM 
therapies 
Of the total sample of patients using CAM therapy (N= 34), 79% (N= 27) thought that 
CAM therapies improved their general health and ensured long term survival, 9% (N 
= 3) recorded that CAM therapies gave them more control over their health, 3% (N = 
1) of the subjects indicated dissatisfaction with conventional medication, 3% (N = 1) 
used them due to family tradition/culture, 3% (N = 1) thought CAM therapies reduced 
the side-effects of conventional medication and 3% (N = 1) gave „other reasons‟ for 
CAM therapy use (Figure 3.2).  
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Figure 3.2: Reasons for CAM therapy use  
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Statistical analysis using the maximum likelihood chi – square test comparing pooled 
reasons for CAM therapy use between the ARV treatment group (N = 26) and the 
non – ARV treatment group found no significant (p = 0.13) difference. However, 81% 
(N = 21) of participants in the ARV treatment group (N = 26) indicated their main 
reason for CAM therapy use was that it improves their general health.   
 
Twenty one (62%) of the 34 CAM users spent on average < £10 per month on CAM 
therapies, 12% (N = 4) spent between £11 and £20, 15% (N = 5) spent on average 
£21 - £30, 6% (N = 2) spent between £31 - £40, 3% (N = 1) indicated spending 
between £41 - £50 and 3% (N = 1) spent > £50. Statistical analysis using the Chi-
square test between the ARV treatment group (N = 26) and the non- ARV treatment 
group (N = 8) in terms of monthly expenditure was not significant (p = 0.62). From the 
total sample of 34 subjects, 44% (N = 15) were unemployed. 80% (N = 12) of these 
44% unemployed subjects indicated that they spent on average < £10 per month on 
CAM therapies, 15% (N = 2) spent between £21 - £30 and 7% (N = 1) spent on 
average £11 - £20. 
 
3.2.3 Sources of information about CAM therapies  
Thirty two percent of participants reported receiving information about CAM therapies 
from health care professionals (doctors, nurses, and dietitians), 12% from Traditional 
Healers, health food stores and internet/articles/newspapers respectively. A further 
9% received information from other non-positive HIV friends/relatives, 6% from 
alternative therapist, HIV positive friend and HIV/AIDS organizations respectively and 
6% indicated „other‟ as a source of information about CAM therapies.  
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The Chi-square statistical test was used to indicate whether ARV treatment and non-
treatment groups‟ sources of information differed significantly. The results indicated 
that there was no difference between the ARV treatment group (N = 26) and the non- 
ARV treatment group (N = 8) in obtaining information on CAM therapy (p = 0.63). 
 
3.2.4 Disclosure of CAM therapy use 
Subjects were asked whether they disclosed the use of CAM therapy to their doctor 
or primary care provider. Seventy three percent (N = 25) of participants reported not 
discussing CAM therapy use with their doctor or primary care provider. Statistical 
analysis (Chi-square test) between the ARV treatment group (N = 26) and non – ARV 
treatment group (N = 8) showed no difference between the 2 groups (p = 0.43).  
 
3.2.5 Knowledge regarding antiretroviral treatment and CAM therapy drug - 
herb interactions  
Eighteen (53%) of the participants were aware of possible ARV drug interactions with 
CAM therapies especially herbal remedies. Statistical analysis using the Chi-square 
test, compared the knowledge of ARV drug - herb interactions between the ARV 
treatment group (N = 26) and the non- ARV treatment group (N = 8). The results 
might indicate that patients in the ARV treatment group had more awareness than 
the non – ARV treatment group (p = 0.006). 
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CHAPTER 4: DISCUSSION 
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The main purpose of this research project was to determine CAM therapy use 
amongst adult HIV infected patients in an outpatient setting. The research project 
also set out to identify why patients with HIV access these therapies, monthly 
expenditure on these CAM therapies, sources of information regarding CAM, 
disclosure to their primary health care provider and knowledge regarding possible 
drug interactions between ARV‟s and herbal remedies. A total of 81 patients were 
included in the study, of which thirty-four patient questionnaires of CAM users could 
be assessed for statistical purposes.  
4.1 CAM Therapy Use 
The prevalence of CAM therapy use in this population was 53%, therefore rejecting 
the null hypothesis. In this study the majority of patients (85%) did not think that CAM 
therapy cured HIV. Rather, CAM therapies were used to complement ARV treatment. 
The high prevalence of CAM therapy use in conjunction with ARV treatment in our 
study highlights the urgent need for doctors and health care professionals (and all the 
other potential resources where patients get CAM information) to understand the 
health benefits and risks of using CAM therapies along with ARV treatment in people 
living with HIV/AIDS. 
In line with previous studies, multivitamins and minerals were most commonly used 
as CAM therapy in CAM users. Previous research by Gore-Felton et al. indicated that 
mega-doses of vitamins are not uncommon amongst HIV-positive patients 55, 49, 
however the efficacy and safety of such a practice amongst this population is still 
unknown. A study by Fawsi et al. (2004) indicated that a multivitamin 
supplementation delayed the progression of HIV disease.47 It can also provide an 
alternative and effective low-cost means of delaying the start of ARV treatment in HIV 
  
 45 
–positive women in resource poor settings. Another study 46 found that micronutrient 
supplementation can significantly improve CD4 cell count in HIV-positive patients 
taking ARV treatment. The micronutrient tested was well tolerated by the patients 
and it has been suggested that micronutrients could be used as an adjuvant to ARV 
treatment. More research, however, is warranted and patients should be informed of 
the risks of mega-doses of micronutrients in terms of toxicity and interactions with 
ARV treatment. 
In our study, garlic was used by 44% of the study participants. As was mentioned 
earlier in chapter 1, severe gastrointestinal side effects have been reported with the 
simultaneous use of Ritonavir and garlic supplements.34 Piscitelli et al. found that 
garlic supplements reduced the concentration of Saquinavir by more than 50%.40 It 
has been recommended that patients should use caution when combining garlic 
supplements with Saquinavir when used as a sole PI.40  
Results from this study indicated that 27% of the participants used Echinacea. The 
use of Echinacea for people with HIV remains controversial. There is no known 
published research to document any dangerous results from the use of Echinacea by 
people with HIV. However, further study is needed as in vitro studies have shown in 
increase in tumor necrosis factor, which could worsen HIV infection.  
St. John‟s Wort was used by 6 participants (18%) in this study. Considering the well 
documented drug-herb interactions between St. John‟s Wort and Indinaivir and 
nevirapine respectively, patients should be advised to avoid co-administration of 
these two herbal therapies with St. John‟s Wort. Co-administration may result in 
suboptimal antiretroviral drug concentrations, leading to loss of virologic failure and 
development of resistance or class cross-resistance. 35, 36 
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Only 2 participants in this study indicated that they‟ve used Sutherlandia and another 
2 subjects used African potato. Investigators have identified the potential for clinically 
significant antiretroviral drug interactions as both Sutherlandia and African potato 
inhibited CYP3A4 and P-glycoprotein expression in-vitro. Caution should be taken 
when introducing these herbal drugs into the routine care of HIV positive people38,39.   
4.2 Reasons for CAM Therapy use and Monthly Expenditure  
In our study, we found that for many people living with HIV/AIDS the most important 
reason for using CAM therapy is the belief that CAM improves their general health 
and ensures long-term survival. In contrast a previous study 29 found that CAM 
therapies are used to reduce and manage the side effects of ARV treatment. A study 
in the US 30 found that many people living with HIV/AIDS used CAM therapies 
because they believed that CAM therapies can reduce the symptoms of HIV infection 
and side-effects of the ARV treatment. In our study only 3% (N = 1) indicated that 
CAM therapy use was associated with reduction of ARV treatments side effects. 
Studies amongst adults with chronic diseases such as cancer, arthritis, 
cardiovascular disease, diabetes and lung disease, indicate that adults with 
diagnosed chronic diseases are more likely to use CAM therapies compared to 
adults with none of the reported chronic diseases.56 As the majority of HIV-infected 
outpatients in this study are CAM users, it can be concluded that HIV-infected 
patients display similar tendencies as patients with other chronic diseases. 
Other potential reasons for the use of CAM therapies, included fighting HIV or 
boosting immunity, relieving stress or depression, improving memory or 
concentration and increased weight gain were not included in this questionnaire, on 
recommendation from the Research and Development committee at Whipps Cross 
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Hospital. The committee thought that the inclusion of all these factors would make it 
too long and cumbersome for the patients and can be seen as a limitation of this 
study. These factors were also not mentioned in question 8 of section C and D of 
questionnaire named „other‟. However, these do require further research. 
Interestingly this project has found that the study subjects spent an average of <£10 
a month on CAM therapies. Persons living below a certain income level may be less 
able or willing to buy CAM therapies. However we found that 44% of this study‟s 
participants were unemployed of which 80% spent on average < £10/month on CAM 
therapies. Weekly income support benefit in the UK is on average £59 per week. 
Spending an average of £10 on CAM therapy therefore disposes a significant amount 
of income. A study by Fairfield et al. (1998) indicated that CAM therapies were 
predominantly paid for out-of-pocket and this burden might be substantial for low-
income groups. From our study one can conclude that income and employment 
status did not predict CAM use. This is an interesting finding and should be further 
explored in future research.  
4.3 Sources of Information regarding CAM  
In our study most of the participants (32%) indicated that they received information 
regarding CAM from their doctor or other health care professionals. This is consistent 
with a study by Gore-Felton et al., who found that medical professionals were the 
most important information source regarding CAM therapies. In contrast with a study 
conducted by De Visser et al. (2000) which indicated that HIV–positive people 
received information from other PLWHA, HIV/AIDS magazines/newsletters and the 
HIV positive community. A major source of information in the HIV population is the 
Internet, HIV related TV and HIV magazines.29 It is debatable whether access to  
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these resources are dependant on the HIV positive patient disclosing their status to 
family/friends  Therefore one can hypothesis that our study participants who have not 
disclosed their status to families/friends for fear of isolation/stigma, also might not 
access these sources of information. Therefore, they might not play an active role in 
the HIV community or spent any time with other HIV-positive people. This, however, 
is highly speculative and further research is warranted.   
4.4 Disclosure of CAM Therapy Use 
Results of our study suggested that most of the participants (73%) did not disclose 
their CAM therapy use to their doctor or health care professional and 32% reported 
that their main source of information for CAM therapy came from health 
professionals.  In the absence of published research, one can only hypothesise that 
this is related to a lack of knowledge from both healthcare providers and patients that 
CAM therapy can interfere with ARV treatment. Due to this, both parties might deem 
it unnecessary to mention or ask about its use.  It is therefore important to address 
this lack of knowledge in primary health care providers working with HIV -patients. 
Given the large proportion of people living with HIV/AIDS, as well as the proportion of 
patients using CAM therapies, it is important that doctors and other health care 
professionals develop a greater awareness of the prevalence of use as well as 
possible drug interactions.  
4.5 Knowledge Regarding Interactions between ARV’s and Herbal Remedies  
Most of the participants in our study were aware of possible drug interactions 
between ARV treatment and herbal remedies. There was a significant difference 
between HIV positive patients taking ARV treatment and ARV treatment-naïve 
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patients in terms of possible drug-herb interactions. One could speculate that due to 
patients taking ARV treatment they take a more active role in their health and 
treatment, and are therefore more aware of possible drug interactions. Currently, the 
protocol in DOSH requires that all HIV positive patients to start on ARV treatment 
have a consultation with both the HIV specialist pharmacist and Dietitian. Both the 
Dietitian and Pharmacist would question the patient about CAM therapy use. This 
may highlight the potential interactions to the patient taking ARV treatment, which 
may explain the significant difference in the knowledge between the ARV treatment 
group and the ARV treatment-naïve group.  
4.6 Limitations of this Study 
Our study has several limitations. Firstly, the convenience sampling method could be 
seen as a limitation. A convenience sample chooses the individuals that are easiest 
to reach.  In this study, it meant that all patients that attended the clinic were eligible 
for the study. Convenience sampling does not represent the entire population so it is 
considered bias, therefore, if clinics were not attended, they would not have been 
approached to participate in the study. Thus, caution should be used when 
generalizing these findings to all people living with HIV/AIDS in the Borough of 
Waltham Forest where this study was conducted.  
However, even with this limitation, the prevalence of CAM therapy use indicates that 
further clinical studies are needed to determine the long-term efficacy of CAM 
therapy use in conjunction with ARV drugs.   
Another limitation was our choice of CAM therapies. Whilst our choice of CAM 
therapies included a multivitamin/mineral supplementation, vitamin E and Selenium, 
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we did not include other single vitamins and minerals such as iron, Vitamin B12, folic 
acid or other that are often recommended or prescribed by medical doctors. The 
reason for not including specific micronutrients and dosages are related to the CAM 
therapy classification, which was used as the basis for the questionnaire. An 
indication of how many patients are taking micronutrient doses above the 
recommended dietary requirements could have been valuable in determining the risk 
of micronutrient toxicity in our population group.   
The inclusion or exclusion of certain CAM therapies can change prevalence 
estimates. Our findings can therefore not be generalized to HIV positive patients in 
other boroughs of London and other counties in the UK, or to patients who did not 
participate in this study.  In our study we made use of the universal definition for CAM 
use.   
The limited number of herbal therapies included in this study might be interpreted as 
a limitation. However, the use of herbal therapies are not as common in the UK as in 
developing countries.38 Therefore the questionnaire included only those herbal 
remedies most commonly used in the UK.    
Our small sample size is also considered a limitation. The design for the study was 
chosen because of the number of participants for this study was dependant on clinic 
attendances during the study period as well as patients‟ consent to participate. 
Additionally, follow – up of well-controlled HIV patients only occurred once a year in 
the clinic where the study was performed. Despite these limitations the investigator 
recruited 112 patients out of a possible 367 patients in this clinic during the 5 month 
study period that was willing to read the study information sheet. The findings may 
certainly not be representative of patients in the UK, but does provide a good 
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indication of the level of CAM therapy use in the local Whipps Cross area and may 
be used as a pilot study for further research in this area.   
There was a statistical difference between the ARV (N = 26) and non- ARV group (N 
= 8). This could be seen as a limitation of this study in terms of a higher prevalence 
of CAM use amongst HIV – infected individuals not on ARV treatment and those on 
ARV treatment. However, a study by Joseph et al. (2003) demonstrated similar rates 
of CAM use amongst ARV and non – ARV patients.61   
Finally, the use of articles only in the English language may be seen as a limitation. 
However, only a few studies on the Pubmed website were published in other 
languages and the gross majority were in English. The investigator was also limited 
to the English language and did not have additional funding for the translation of 
articles.   
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CHAPTER 5: CONCLUSION 
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Complimentary and alternative medicine therapies can be defined as those therapies 
not generally taught in Western medical schools (according to current data available) 
and not generally prescribed by providers of medical care in Western tradition (i.e. 
medical care in the US). The use of CAM therapies is common amongst the general 
population (accounting for substantial expenditures) 10 and could be substantially 
more prevalent among people living with HIV/AIDS. 28,29,30,55 Limited evidence is 
available in the UK regarding the safe and effective use of CAM in the treatment of 
HIV/AIDS. Our results indicated that 85% of the participants did not believe CAM 
therapies cure HIV/AIDS. One can speculate that CAM therapies are used by HIV 
infected patients in this sample group not as an alternative to conventional treatment 
but to complement conventional treatment. 
The use of CAM therapies by PLWHA and the known contraindications of certain 
ARV drug and some herbal remedies highlight the need to discuss CAM therapy use 
routinely as part of any discussion or treatment for HIV/AIDS patients. This might 
require physicians and other health care professionals to increase their knowledge 
about CAM therapies. However, there are still many gaps in our understanding of 
CAM therapies and possible interactions between ARV treatment and CAM 
therapies. 
Based on the lack of evidence and following on from this study, one outcome of this 
project was the development of an algorithm (Appendix 6a and Appendix 6b) of CAM 
therapy use. This algorithm could be used to assess CAM therapy use amongst HIV 
positive patients. Physicians and other health care professionals would be able to 
determine the patterns and extent of CAM therapy use by the patients.  Our findings, 
especially those regarding the contraindications of taking St. John‟s Wort in 
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conjunction with Nevirapine 35 and Indinavir 34, as well as garlic with Saquinavir 40 
highlight the need for doctors and health care professionals to be aware of any CAM 
therapies that HIV positive patients are taking. Therefore the need for a CAM therapy 
algorithm. The algorithm illustrates the most well documented herbal remedies, drug-
herb interactions as well as micronutrients and toxicity levels.  The individual 
pathways for each CAM therapy are also shown and provide a quick reference tool to 
determine different outcomes are shown in the tool to assist health care providers to 
make decisions based on current evidence. In addition this algorithm may empower 
primary health care providers to manage a patient‟s treatment regimen with or 
without CAM therapy. A further audit process will be conducted to evaluate the 
effectiveness of the algorithm, its use among health care professionals and updating 
the algorithm as new data become available.  
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Appendix 3: Information sheet 
Whipps Cross University Hospital 
Azalea Ward 
Whipps Cross Road 
Leytonstone 
London E11 1NR 
 
Tel: 020 8535 6705 
Fax: 020 8535 6760 
Project title: 
 
A survey investigating the use of complementary and alternative therapies (CAM) among adult HIV-
infected patients in an outpatient setting 
 
You are being invited to take part in a study.  Before you decide it is important for you to 
understand why the project is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with others if you wish.  Ask us if there is 
anything that is not clear or if you would like more information.  Take time to decide whether or 
not you wish to take part. 
 
Thank you for reading this 
 
 
What is the purpose of the project? 
 
The term complementary and alternative therapies (CAM) are used to describe therapies other than 
conventional medical interventions (Anti – HIV treatment etc).  Recent research has shown that the 
use of CAM among HIV infected people is on the increase.  The high prevalence of CAM use among 
HIV infected patients suggests that complementary and alternative therapy use is an important part of 
their health management.  The purpose of this research is to examine the use of complementary and 
alternative therapies among adult HIV-infected patients in an ethnically diverse population and to 
create an awareness of the potential drug-herb interactions among those patients using CAM 
therapies.   
 
This study is conducted at the Department of Sexual Health in Whipps Cross University Hospital.  All 
patients attending the clinic between August and November 2005 will kindly be asked to participate.   
 
Why have I been chosen? 
 
As a patient of DOSH (Department of Sexual Health) at Whipps Cross University Hospital you are 
invited to participate in this research to help us understand the role of complementary and alternative 
therapies in HIV/AIDS. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part you are still 
free to withdraw at any time and without giving a reason.  A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. 
 
 
 
What will happen to me if I take part? 
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The study will be conducted as a questionnaire, and it will take you less than 20 minutes to complete 
the questionnaire. It will take 6 months to collect and analyse the data collected. Please be assured 
that your responses will be completely confidential. 
 
 
What are the possible benefits of taking part? 
 
There will be no direct benefits arising from your participation; however it might encourage sharing 
your complementary and alternative therapy (CAM) use with your clinic doctor/other health 
professional.   
 
What if something goes wrong? 
 
For negligent harm normal NHS indemnity applies as Whipps Cross University Hospital Trust 
sponsors this study. 
 
There are no special arrangements to cover non-negligent harm. If a participant was harmed as a 
result of this study they may pursue a claim for negligence through litigation. 
 
Will my taking part in this project be kept confidential? 
 
All information that is collected about you during the course of the research will be kept strictly 
confidential.  Any information about you that leaves the hospital will have your name and address 
removed so that you cannot be recognised from it. Anonymised data will be stored on a personal 
computer, which is password protected. Completed questionnaires and consent forms will be kept in a 
locked filling cabinet at the Department of Sexual Health (DOSH). Anonymised data will be sent to the 
Department of Human Nutrition, University of Stellenbosch, South Africa for analysis.  
 
Who is organizing and funding the project? 
 
Department of Human Nutrition, University of Stellenbosch, South Africa.  
  
 
What will happen to the results of the project? 
 
Data will be reported in a thesis for the Master‟s degree in nutrition and submitted for publication in a 
peer-reviewed professional journal. 
 
Who has reviewed the project? 
 
The study was submitted for ethical approval at the NHS Central Office for Research Ethics 
Committee, as well as at the Committee for Human Research, Faculty of Health Sciences, University 
of Stellenbosch, South Africa. 
 
Contact for Further Information 
 
You can contact the principle investigator, Charlé Aucamp (Senior Dietitian) at 0208 535 6776 during 
office hours Monday to Friday, or by email at the following address: charle.aucampc@whippsx.nhs.uk if 
you have any further queries. 
 
 
 
Thank you for your participation! 
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Appendix 4: Questionnaire 
      
                                                                                                                               
 
A survey investigating the use of complementary and alternative 
therapies (CAM) among adult HIV-infected patients in an 
outpatients setting 
 
REFERENCE NUMBER: ______________ 
 
PATIENT QUESTIONNAIRE 
 
Have you ever used or are using complementary and alternative therapies (CAM)?  
  
                                                   
 
 
If NO, you do not need to complete this questionnaire. Thank you for your time. 
 
If YES, please continue to Section A. 
 
 
SECTION A: SOCIO-DEMOGRAPHIC INFORMATION 
 
1. Which of the following best describes your education (please tick). 
 
A. Secondary/ High School 
 
B. College 
 
C. University 
 
D. Post Grad Education 
 
 
2. Employment Status (please tick) 
 
A. Full time paid employment 
 
B. Part time paid employment 
 
C. Self employed/freelance 
 
D. Unemployed 
 
E. Student 
 
 
 
Please continue to section B (Page 3) 
1 
2 
3 
1 
2 
3 
4 
5 
YES       NO 
4 
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SECTION B: YOU AND HIV 
 
 
3. How long have you been aware of your HIV status? (please tick) 
 
A.   <3 months  
  
B.    3 – 11 months 
   
C.    1 – 5 years  
  
D.    > 5 years 
 
 
4. Your current state of health (please tick) 
 
A.   Very poor   
 
B.   Poor    
  
C.   Fair 
    
D.   Good  
 
E.   Excellent                                           
 
 
5.  Are you currently using HIV medication?             
 
If NO, please continue to Section C                           (PAGE 4)  
 
 
 
If YES, please continue to Section D                         (PAGE 7) 
 
1 
2 
3 
4 
1 
2 
3 
4 
5 
YES   NO 
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SECTION C:  I AM NOT CURRENTLY ON ANTI-HIV 
TREATMENT 
 
6. Which of the following complementary and alternative therapies have you used in the 
past 6 months (please tick all appropriate boxes) 
 
Alternative therapy Never used Used in the 
past 
Used at 
present 
Herbal Remedies    
Ayurvedic medicine    
Chinese medicine    
Tibetan medicine    
St. John‟s Wort    
Echinacea    
Ginseng    
Garlic    
Sutherlandia    
African Potato (Hypoxis)    
Other (please specify)    
    
    
Nutritional Supplements/Vitamins 
   
Selenium    
Glutamine    
Vitamins E    
Multivitamin/mineral supplement    
Other (please specify)    
    
Lifestyle/Homeopathy 
   
Prayer/ faith healing    
Meditation/ visualization    
Yoga    
Exercise    
Reiki    
Acupuncture    
Massage    
Chiropractic therapies    
Other (please specify)    
    
    
 
 
7. When did you start using these complementary and/or alternative therapies? (please tick) 
 
a. Before my HIV diagnosis 
 
b. After my HIV diagnosis 
 
 
 
 
 
 
 
 
1 
2 
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8. Why do you use complementary and/or alternative therapies? (please tick all that apply) 
 
A. Dissatisfaction with conventional medication 
 
B. You think it improves your general health and ensure long term survival 
 
C. Family tradition/ Culture 
 
D. Reduce the side effects of conventional medication 
 
E. More personal control over your health care 
 
F. You think it is more natural 
 
G. Curiosity 
 
H. I think it has anti- HIV properties 
 
I. Other (please describe) 
_____________________________________________________________________
_____________________________________________________________________
_______________________________________________________________ 
 
 
9. Where do you get your information on alternative therapies? (please tick all that 
        apply) 
 
A. My Doctor/ nurse/ other health care professional 
 
B. Alternative therapist   
 
C.  HIV positive friend 
 
D.   HIV/AIDS organization 
 
E.  Other friend/ relative 
 
F.  Traditional healer 
 
G. Health Food Stores 
 
H. Internet/articles/newspapers  
 
I. Other, (please specify) 
_____________________________________________________________________
_____________________________________________________________________
________________________________________________    
 
 
 
10. On average, how much do you spend per month on complementary and/or 
      alternative therapies? (please tick) 
                                             
 
 
 
 
 
1 
2 
3 
4 
5 
6 
7 
8 
1 
2 
3 
4 
5 
6 
7 
8 
< £10          £11 – 20               £21 – 30          £31 – 40             £41 – 50              > £51 
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11. Did you consult your Doctor/other Health Care Professional before starting  
      complementary and/or alternative therapies (please tick) 
 
  
 
 
 
12.  Are you aware of any possible drug interactions with complementary and/or  
       alternative therapies especially herbal remedies? (please tick) 
 
 
 
 
 
 
13.  Do you belief complementary therapies and nutritional supplements cures  
       HIV/AIDS? 
 
 
 
  
 
 
 
 
 
 
 
 
THANK YOU FOR YOU PARTICIPATION 
 
YES       NO 
YES       NO 
  YES         NO 
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SECTION D: I AM CURRENTLY ON ANTI-HIV TREATMENT 
 
 
14.  For how long have you been on combination therapy? (please tick) 
 
 
  
 
 
 
15.  Which of the following symptoms did you experience in the past 6 months? 
       (please tick all that apply) 
 
10. Nausea 
   
11. Vomiting  
  
12. Loss of appetite 
 
13. Diarrhoea 
 
14. Constipation 
 
15. Pain body/ muscle limb pain 
 
16. Loss of taste/ smell 
 
17. Other (please specify) _____________________________________  
 
 
16. Which of the following complementary and alternative therapies have you used in the 
past 6 months (please tick all appropriate boxes) 
 
 
Alternative therapy Never used Used in the 
past 
Used at 
present 
Herbal Remedies    
Ayurvedic medicine    
Chinese medicine    
Tibetan medicine    
St. John‟s Wort    
Echinacea    
Ginseng    
Garlic    
Sutherlandia    
African Potato (Hypoxis)    
Other (please specify)    
    
    
Nutritional Supplements/Vitamins 
   
Selenium    
Glutamine    
Vitamins E    
Multivitamin/mineral supplement    
Other (please specify)    
    
    < 3 months                 3-11 months             1-5 years               > 5 years 
1 
2 
3 
4 
5 
6 
7 
8 
  
 72 
Lifestyle/Homeopathy 
   
Prayer/ faith healing    
Meditation/ visualization    
Yoga    
Exercise    
Reiki    
Acupuncture    
Massage    
Chiropractic therapies    
Other (please specify)    
    
    
 
 
17. When did you start using these complementary and/or alternative therapies? (please tick) 
 
A.  Before my HIV diagnosis 
 
B.  After my HIV diagnosis 
 
 
 
18.Why do you use complementary and/or alternative therapies? (please tick all that apply) 
 
A    Dissatisfaction with conventional medication 
 
B    You think it improves your general health and ensures long term 
      survival 
 
C. Family tradition/ Culture 
 
D. Reduce the side effects of conventional medication 
 
E. More personal control over your health care 
 
F. You think it is more natural 
 
G. Curiosity 
 
H. I think it has anti-HIV properties 
 
I. Other (please describe) 
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
____________ 
 
 
19.  Where did you get your information on complementary and alternative therapies? (please 
tick all that apply). 
  
A. My Doctor/ nurse/ other health care professional               
 
B.  Alternative therapist   
 
C.  HIV positive friend 
 
D.   HIV/AIDS organization 
1 
2 
3 
4 
1 
2 
3 
4 
5 
6 
7 
8 
1 
2 
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E.  Other friend/ relative 
 
F.  Traditional healer 
 
G. Health Food Stores                                         
 
H. Internet/articles/newspapers  
 
I. Other, (please specify) 
_____________________________________________________________________
_____________________________________________________________________
________________________________________________    
 
 
20. On average, how much do you spend per month on complementary and/or alternative 
therapies? (please circle) 
 
                                             
 
 
 
21.Did you consult your Doctor/other Health Care Professional before starting  
     complementary and/or alternative therapies (please tick) 
 
  
 
22.Are you aware of any possible drug interactions with complementary and/or  
     alternative therapies especially herbal remedies? (please tick) 
 
 
 
 
23.  Do you belief complementary therapies and nutritional supplements cures  
       HIV/AIDS? 
  
 
 
 
 
 
 
 
 
THANK YOU FOR YOU PARTICIPATION 
 
 
 
 
 
 
 
 
 
 
 
 
8 
7 
5 
6 
9 
< £10      £11 – 20      £21 – 30              £31 – 40             £41 – 50          > £51 
 
YES       NO 
YES       NO 
YES        NO 
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MALE           FEMALE 
2 
Appendix 5: Investigator data collection sheet 
 
 
 
 
A survey investigating the use of complementary and alternative therapies 
(CAM) among adult HIV-infected patients in an outpatient setting 
  
INVESTIGATOR DATA COLLECTION FORM 
 
REFERENCE NUMBER: __________________________ 
 
DEMOGRAPHIC INFORMATION 
 
1.  Gender (please tick)                                          
 
2.  Age:  ___________ 
 
3.  Which ethnic group does the patient belong to? (please tick) 
 
 
White      British 
      Irish 
      Other White, please specify__________   
 
Mixed      White and Black Caribbean 
      White and Black African 
      White and Asian 
      Other mixed, please specify__________  
Asian/British Asian                   Indian 
      Pakistani 
      Bangladeshi 
        Other Asian, please specify__________ 
 
Black or Black British                Caribbean 
      African 
      Other Black, please specify__________  
Other ethnic categories   Chinese 
      Any other, please specify____________  
 
Not stated     Not stated 
 
 
       
                            
4. Is the participant currently using HIV combination therapy? (please tick)  
 
 
 
If NO, you have collected all the data 
 
If YES, which combination: (please circle) 
 
1 
3 
4 
6 
5 
7 
8 
9 
11 
10 
12 
13 
14 
15 
16 7 
YES           NO 
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NRTI’s NNRTI’s PI’s Dual and boosted 
Protease 
combinations 
Entry Inhibitors 
(fusion inhibitors) 
D4T (Zerit, stavudine) Efavirenz 
(sustiva) 
Indinavir 
(crixivan) 
Lopinavir/r (kaletra) Enfuvirtide (T-20, 
fuzeon) 
AZT (Retrovir, 
zidovudine 
Nevirapine 
(viramune) 
Nelfinavir 
(viracept) 
Indinavir/ritonavir   
ddI (videx, didanosine) Delavirdine 
(rescriptor) 
Atazanavir 
(reyataz) 
Saquinavir/ritonavir  
3TC (epivir, lamivudine)   Fosaprenavir/ritonavir  
Abacavir (Ziagen)   Atazanavir/ritonavir  
Combivir (AZT/3TC)   Tipranavir/ritonavir  
Trizivir 
(AZT/3TC/abacavir) 
    
Tenofovir (viread)     
FTC (emtracitabine)     
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